General
Preferred name
miglustat
Synonyms
N-Butyldeoxynojirimycin, Hydrochloride ()
NB-DNJ hydrochloride ()
OGT918 hydrochloride ()
N-Butyldeoxynojirimycin ()
OGT918 ()
NB-DNJ ()
Miglustat hydrochloride ()
Miglustat HCl ()
Zavesca ()
Miglustat (hydrochloride) ()
OGT 918 ()
N-Butyldeoxynojirimycin (hydrochloride) ()
NB-DNJ (hydrochloride) ()
OGT 918 (hydrochloride) ()
Zavesca, N©\butyldeoxynojirimycin, OGT 918 ()
N-Butyldeoxynojirimycin (hydrochloride) ()
Butyldeoxynojirimycin ()
Miglustat gen.orph ()
Opfolda ()
Yargesa ()
OGT-918 ()
Miglustat dipharma ()
N-Butyldeoxynojirimycin-d9 (hydrochloride) ()
P&D ID
PD010037
CAS
210110-90-0
72599-27-0
134282-77-2
1883545-57-0
Tags
available
prodrug
drug
Approved by
FDA
EMA
First approval
2002
Drug indication
Type 1 gaucher disease
HIV infection
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease[1][2].
PRICE
90
DESCRIPTION
Miglustat is a glucosylceramide synthase inhibitor. Marketed formulations may contain miglustat hydrochloride (PubChem CID 71299591).
(GtoPdb)
DESCRIPTION
Antianginal, activates pyruvate dehydrogenase
(Tocris Bioactive Compound Library)
DESCRIPTION
Miglustat (NB-DNJ) is an alkylated product of imino sugar deoxynojirimycin.It is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
(TargetMol Bioactive Compound Library)
DESCRIPTION
Miglustat is an inhibitor of glucosylceramide synthase. It is used for the management of mild to moderate type I Gaucher disease for patients who are not candidates for whole enzyme replacement.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
3
Compound Sets
33
AdooQ Bioactive Compound Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Pandemic Response Box
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
67
Molecular Weight
219.15
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
4
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
0
cLogP
-1.45
TPSA
84.16
Fraction CSP3
1.0
Chiral centers
4.0
Largest ring
6.0
QED
0.46
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
ceramide glucosyltransferase inhibitor
Inhibitor
SGLT-3 Activators
Pharmacological Chaperones
alpha-Glucosidase Inhibitors
Ceramide Glucosyltransferase Inhibitors
glycosyl transferase inhibitor
Target
Ceramide glucosyltransferase
UGCG
Glucosylceramide Synthase (GCS)
Transferase
Primary Target
Glycosylases
Member status
member
Indication
Gaucher disease
Biosynthetic Origin
Carbohydrate
Therapeutic Indication
Gaucher's Disease
Therapeutic Class
Metabolic Disorders
Anti-HIV Agents
Pathway
Neuronal Signaling
Source data
